Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

Lundbeck Australia Pty Ltd

Sunday, 15 October, 2017

Rexulti group 02

October 1st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia. REXULTI works on three neurotransmitter systems: serotonin, dopamine and noradrenaline.1

The efficacy and safety of REXULTI have been demonstrated in two short-term studies and one long-term maintenance trial.1

REXULTI tablets are taken once daily and come in dose strengths of 1 mg, 2 mg, 3 mg and 4 mg with a recommended target dose of 2-4 mg/day.

Lundbeck Australia and Otsuka Australia Pharmaceutical are dedicated to bringing innovative new medicines to Australians with psychiatric disorders.

Please review the REXULTI Approved Product Information before prescribing. Product information is available by calling Lundbeck on 1300 721 277 or click here.

1. REXULTI® Australian Approved Product Information.

Related Sponsored Contents

ATP: rapid hygiene testing in health care

Hygiena ATP testing devices contain a natural enzyme found in fireflies. This enzyme produces a...

Changing how hospitals disinfect TOE probes

The TD 100CE automated TOE probe disinfector is designed to provide high-level disinfection of...

Antibiotic resistant organisms a growing problem worldwide

Antimicrobial resistant organisms are a common cause of infections in healthcare facilities. Such...

  • All content Copyright © 2019 Westwick-Farrow Pty Ltd